A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

J Eur Acad Dermatol Venereol. 2016 May;30(5):864-5. doi: 10.1111/jdv.13032. Epub 2015 Mar 13.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Humans
  • Psoriasis / drug therapy*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • ixekizumab

Associated data

  • GENBANK/NCT01107457